Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
Vigil Neuroscience, Inc. (VIGL)
Company Research
Source: GlobeNewswire
– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer’s Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 – – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided updates on recent progress. “We are entering 2025 with strong momentum, driven by significant progress in the develop
Read more
Impact Snapshot
Event Time:
VIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIGL alerts
High impacting Vigil Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
VIGL
News
- Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target lowered by analysts at Wedbush from $24.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target lowered by analysts at HC Wainwright from $17.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum [Yahoo! Finance]Yahoo! Finance
- Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS ForumGlobeNewswire
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)PR Newswire
VIGL
Earnings
- 11/7/24 - Beat
VIGL
Sec Filings
- 3/31/25 - Form S-3
- 3/31/25 - Form ARS
- 3/31/25 - Form DEFA14A
- VIGL's page on the SEC website